LAVA Therapeutics NV [LVTX] Stock trading around $2.23 per share: What’s Next?

LAVA Therapeutics NV [NASDAQ: LVTX] stock went on an upward path that rose over 42.95% on Thursday, amounting to a one-week price increase of more than 41.14%. The company report on January 25, 2024 at 7:00 AM that LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®.

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Enrollment will continue in the monotherapy and IL-2 combination arms of the study.

Over the last 12 months, LVTX stock dropped by -33.63%. The one-year LAVA Therapeutics NV stock forecast points to a potential upside of 61.22. The average equity rating for LVTX stock is currently 1.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $58.63 million, with 26.29 million shares outstanding and 12.24 million shares in the current float. Compared to the average trading volume of 36.64K shares, LVTX stock reached a trading volume of 43174474 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on LAVA Therapeutics NV [LVTX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LVTX shares is $5.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LVTX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for LAVA Therapeutics NV shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 25, 2022.

The Average True Range (ATR) for LAVA Therapeutics NV is set at 0.14, with the Price to Sales ratio for LVTX stock in the period of the last 12 months amounting to 6.47. The Price to Book ratio for the last quarter was 1.07, with the Price to Cash per share for the same quarter was set at 3.98.

LVTX Stock Performance Analysis:

LAVA Therapeutics NV [LVTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 41.14. With this latest performance, LVTX shares gained by 47.68% in over the last four-week period, additionally plugging by 15.54% over the last 6 months – not to mention a drop of -33.63% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LVTX stock in for the last two-week period is set at 78.13, with the RSI for the last a single of trading hit 82.59, and the three-weeks RSI is set at 74.74 for LAVA Therapeutics NV [LVTX]. The present Moving Average for the last 50 days of trading for this stock 1.5800, while it was recorded at 1.6900 for the last single week of trading, and 1.6900 for the last 200 days.

Insight into LAVA Therapeutics NV Fundamentals:

LAVA Therapeutics NV’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.20.


With the latest financial reports released by the company, LAVA Therapeutics NV posted -0.57/share EPS, while the average EPS was predicted by analysts to be reported at -0.64/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LVTX.

LAVA Therapeutics NV [LVTX] Institutonal Ownership Details

The top three institutional holders of LVTX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in LVTX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in LVTX stock with ownership which is approximately 5.8325%.